Antihypertensive de-escalation
Intervention1 paper2 findings
- Human trial1
Outcomes
1Major adverse cardiovascular events
no changein humans1Low certainty
1 study
Major adverse cardiovascular events
no changein humans1Low certainty
Antihypertensive de-escalation has no effect on major adverse cardiovascular events in humans.
Humansin the intensive arm (target SBP <120 mm Hg) with prompt treatment re-intensification
The Impact of Antihypertensive De-escalation: A Secondary Analysis of Systolic Blood Pressure Intervention Trial (SPRINT) · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 19 Sep 2026
Associations
1Major adverse cardiovascular events
upin humans1HR 1.34Low certainty
1 study
Major adverse cardiovascular events
upin humans1HR 1.34Low certainty
Antihypertensive de-escalation raises the risk of major adverse cardiovascular events in humans (HR: 1.34, 95% CI: 1.04-1.74).
Humansunder the standard treatment strategy (target SBP <140 mm Hg)
The Impact of Antihypertensive De-escalation: A Secondary Analysis of Systolic Blood Pressure Intervention Trial (SPRINT) · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 19 Sep 2026